Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech is a clinical‑stage oncology company focused on Annamycin (naxtarubicin), a "next‑generation" anthracycline. It is running the pivotal Phase 2/3 MIRACLE trial in relapsed/refractory AML, where preliminary unblinded Part A data for 45 patients showed complete remission (CR) rates of 43% and 36% in the two Annamycin arms versus 12% for the control, and CRc rates of 50% and 57% versus 29%. Pooled data from five trials (n=90) showed no evidence of drug‑related cardiotoxicity despite high cumulative doses.
For the six months ended June 30, 2026, the company reported no revenue and a net loss of $20.5 million, with R&D of $10.8 million driven largely by MIRACLE. Cash and cash equivalents were $7.3 million against an accumulated deficit of $226.5 million, and management disclosed substantial doubt about its ability to continue as a going concern. Subsequent to quarter‑end, an August 2026 equity/warrant offering raised $9.3 million gross, which, together with existing cash, is expected to fund operations into the first quarter of 2027, but the company estimates it needs roughly $8 million more to support MIRACLE and operations into the second quarter of 2027.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of Moleculin Biotech, Inc. common stock. They collectively report beneficial ownership of 1,863,377 Shares, representing 9.9% of the outstanding common stock. The position consists of 1,400,000 Shares and additional Shares issuable upon exercise of Warrants that are subject to a 9.99% beneficial ownership limitation. Heights Capital Management, Inc., as investment manager to CVI Investments, Inc., may be deemed to share voting and dispositive power over these Shares, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Moleculin Biotech, Inc. is the subject of a Schedule 13G reporting the ownership of common stock by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on August 6, 2025, they may be deemed to beneficially own 973,927 shares of common stock, representing approximately 4.99% of the class. This total includes 203,720 shares held by Intracoastal and 770,207 shares issuable upon exercise of a warrant referred to as Intracoastal Warrant 2, all calculated against a base of 7,100,713 shares outstanding as of July 30, 2026 plus additional shares issued in connection with a Securities Purchase Agreement.
The filing describes prior ownership immediately following execution of the Securities Purchase Agreement on July 31, 2026, when the reporting persons may have been deemed to beneficially own 788,091 shares (about 9.99% of the common stock) including shares to be issued and shares issuable upon exercise of a warrant. Both Intracoastal Warrant 1 and Intracoastal Warrant 2 contain blocker provisions limiting exercisability so that beneficial ownership does not exceed 9.99% or 4.99%, respectively. Without these blocker provisions, the reporting persons may have been deemed to beneficially own up to 5,333,332 shares immediately following the agreement and 4,203,719 shares as of August 6, 2025. The filing states that they now report ownership of 5 percent or less of the class.
On August 3, 2026, Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster purchased 293,333 shares of common stock and 879,999 Series I Warrants in a public offering at a combined price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly held 305,673 shares of common stock and 1,027,717 Series I Warrants to purchase common stock, which are reported with an expiration date of August 3, 2031.
Moleculin Biotech, Inc. director, CEO and President Walter V. Klemp reported acquiring 533,333 shares of common stock in a public offering, together with Series I warrants to purchase 1,599,999 shares. The securities were bought at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants. Following these transactions, he directly holds 564,340 common shares and 1,926,335 Series I warrants, which are exercisable for common stock and expire on August 3, 2031.
Moleculin Biotech, Inc. reports that Chief Science Officer Donald H. Picker purchased 173,333 shares of common stock and Series I Warrants to purchase 519,999 shares on August 3, 2026, in a public offering at a combined purchase price of $0.75 per one share and three warrants. Following these transactions, he directly holds 174,086 common shares and 539,595 Series I Warrants.
Moleculin Biotech entered placement agency and securities purchase agreements for a public offering of 12,376,667 shares of common stock or pre-funded warrants and Series I common stock purchase warrants to buy up to 37,130,001 shares. The combined public offering price is $0.75 per share (or pre-funded warrant) and accompanying warrant, generating approximately $9.3 million in gross proceeds before fees and expenses. The sale closed on August 3, 2026 under an effective Form S-1 registration statement.
The pre-funded warrants are exercisable at $0.001 per share until fully exercised, while the common warrants are exercisable at $0.75 per share for five years after the initial exercise date, subject to 4.99%–9.99% beneficial ownership limits and an exercise price adjustment feature with a $0.21 floor. Net proceeds are intended to advance the Annamycin program through clinical development and for working capital. The company agreed to restrictions on additional equity issuances and variable rate transactions, 60‑day lock-ups for directors and officers, a 6.5% cash fee plus up to $100,000 of expenses to the placement agent, and a 1.0% fee to a financial advisor.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 11,088,334 shares of common stock at $0.75 per share together with 37,130,001 Series I common warrants, plus up to 1,288,333 pre-funded warrants offered in lieu of shares for certain large investors. Each share or pre-funded warrant is sold with three common warrants, each exercisable at $0.75 for five years, with anti-dilution down to a $0.15 floor. Maximum gross proceeds are $9.28 million, with estimated net proceeds of about $8.5 million, before any warrant exercises. The company plans to use the proceeds primarily to advance its lead drug candidate Annamycin in the pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML and for working capital. The offering has no minimum, no escrow, and may close with reduced proceeds, increasing financing risk and dilution. Common shares outstanding are expected to rise from 7,100,713 to 18,189,047 (or 19,477,380 if all pre-funded warrants are exercised), excluding any exercise of the new common warrants.
Moleculin Biotech is reporting updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory acute myeloid leukemia. With 62 subjects evaluable, the blinded complete remission (CR) rate is 24% and the composite complete remission (CRc) rate is 37%.
Of these 62 subjects, 30 (48%) had previously received a venetoclax-based regimen; in this subgroup, blinded CR and CRc rates are 23% and 37%, similar to the overall evaluable population. The analysis remains blinded and includes control-arm patients, and is therefore expected to be below unblinded Annamycin-arm results reported in June, when CRc reached 50% and 57% in the two Annamycin arms versus 29% for control after a single cycle. Enrollment stands at 74 of 90 Part A subjects, with the Company expecting to treat the 90th subject in September 2026 and to unblind comprehensive Part A data in the December 2026 to February 2027 timeframe. Across the trial, the Company reports no evidence of cardiotoxicity, and notes that Annamycin holds Fast Track Status and Orphan Drug Designations for relapsed or refractory AML.